Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections
MUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received approval from the United
Source: benzinga.com